ES2841274T3 - Inmunoterapia con células T específica para WT-1 - Google Patents

Inmunoterapia con células T específica para WT-1 Download PDF

Info

Publication number
ES2841274T3
ES2841274T3 ES15753531T ES15753531T ES2841274T3 ES 2841274 T3 ES2841274 T3 ES 2841274T3 ES 15753531 T ES15753531 T ES 15753531T ES 15753531 T ES15753531 T ES 15753531T ES 2841274 T3 ES2841274 T3 ES 2841274T3
Authority
ES
Spain
Prior art keywords
seq
cell
amino acid
tcr
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15753531T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Schmitt
Philip Greenberg
Hieu Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Application granted granted Critical
Publication of ES2841274T3 publication Critical patent/ES2841274T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES15753531T 2014-08-04 2015-07-30 Inmunoterapia con células T específica para WT-1 Active ES2841274T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033045P 2014-08-04 2014-08-04
US201562164783P 2015-05-21 2015-05-21
PCT/US2015/042986 WO2016022400A1 (en) 2014-08-04 2015-07-30 T cell immunotherapy specific for wt-1

Publications (1)

Publication Number Publication Date
ES2841274T3 true ES2841274T3 (es) 2021-07-07

Family

ID=53901124

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15753531T Active ES2841274T3 (es) 2014-08-04 2015-07-30 Inmunoterapia con células T específica para WT-1

Country Status (7)

Country Link
US (1) US10538572B2 (cg-RX-API-DMAC7.html)
EP (1) EP3177314B1 (cg-RX-API-DMAC7.html)
JP (2) JP6712261B2 (cg-RX-API-DMAC7.html)
CN (1) CN107074970B (cg-RX-API-DMAC7.html)
CA (1) CA2956545A1 (cg-RX-API-DMAC7.html)
ES (1) ES2841274T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016022400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016011567A2 (pt) 2013-11-22 2017-10-24 Hutchinson Fred Cancer Res receptores de célula t humana de alta afinidade geneticamente modificados.
ES2979088T3 (es) 2015-03-05 2024-09-24 Fred Hutchinson Cancer Center Proteínas de fusión inmunomoduladoras y usos de las mismas
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
JP7254519B2 (ja) 2016-04-08 2023-04-10 イムノコア リミテッド Ｔ細胞レセプター
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US11261428B2 (en) 2018-03-15 2022-03-01 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
IL266892B2 (en) 2016-12-02 2025-10-01 Univ Southern California Artificial immune receptors and methods of using them
CN110121336A (zh) 2017-01-05 2019-08-13 弗莱德哈钦森癌症研究中心 改善疫苗功效的系统和方法
JP7131775B2 (ja) * 2017-02-06 2022-09-06 国立研究開発法人国立がん研究センター 新規ｔ細胞受容体
SG11201908527SA (en) * 2017-03-15 2019-10-30 Hutchinson Fred Cancer Res High affinity mage-a1-specific tcrs and uses thereof
JP2020511136A (ja) 2017-03-17 2020-04-16 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
TWI835730B (zh) 2017-04-24 2024-03-21 義大利聖拉斐爾醫院 Ｔｃｒ及肽
NL2019156B1 (en) * 2017-06-30 2019-01-10 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Treatment of haematological malignancies
WO2019004831A1 (en) * 2017-06-30 2019-01-03 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) TREATMENT OF HEMATOLOGICAL MALIGNANCIES
CN107267463A (zh) * 2017-08-23 2017-10-20 安徽惠恩生物科技股份有限公司 一种针对乳腺癌的Car‑NK细胞制备方法
EP4170029A3 (en) 2017-09-19 2023-08-30 Tropic Biosciences UK Limited Modifying the specifity of plant non-coding rna molecules for silencing gene expression
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
TWI805665B (zh) 2017-12-21 2023-06-21 瑞士商赫孚孟拉羅股份公司 結合hla-a2/wt1之抗體
US12280092B2 (en) 2018-01-05 2025-04-22 Nantbio, Inc. Reprogrammed T cell-like NK cells
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス， インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20210015869A1 (en) * 2018-04-05 2021-01-21 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
RU2020135968A (ru) * 2018-04-05 2022-05-06 Джуно Терапьютикс, Инк. T-клеточные рецепторы и модифицированные клетки, экспрессирующие
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN112585162B (zh) * 2018-08-06 2025-01-28 基因医疗免疫疗法有限责任公司 Ha-1特异性t细胞受体及其用途
JP7558151B2 (ja) * 2018-09-05 2024-09-30 アダプティミューン・リミテッド Ｔ細胞改変
TWI851607B (zh) * 2018-10-05 2024-08-11 日商癌免疫研究所股份有限公司 良性腫瘤之預防或治療藥
CN113227374A (zh) 2018-10-16 2021-08-06 因特利亚治疗公司 用于免疫疗法的组合物和方法
GB201817821D0 (en) * 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
CN113784978B (zh) 2019-03-11 2025-07-25 弗雷德哈钦森癌症中心 高亲合力wt1 t细胞受体及其用途
CN111714618B (zh) * 2019-03-22 2024-07-12 香雪生命科学技术（广东）有限公司 T细胞和高亲和力pd-1融合蛋白的组合
EP3750547A1 (en) 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
JP7737978B2 (ja) * 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Ｗｔ－１に特異的なｔ細胞免疫療法
EP4086281A4 (en) * 2019-12-30 2024-02-14 China Immunotech (Beijing) Biotechnology Co., Ltd IMPROVED STAR T CELL RECEPTOR AND ITS APPLICATION
CN114106144B (zh) * 2020-08-27 2024-01-26 溧阳瑅赛生物医药有限公司 识别hla-a*02/wt1靶点的tcr及其应用
WO2022132836A2 (en) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
CA3215997A1 (en) * 2021-04-21 2022-10-27 Connor SWEENEY Method and composition
WO2022246250A1 (en) * 2021-05-20 2022-11-24 Washington University Neuroprotective compositions and methods
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
CN113773378B (zh) * 2021-10-14 2023-11-03 深圳大学总医院 T细胞受体及其应用
EP4423144A4 (en) * 2021-10-29 2025-10-08 Yafei Hou T CELL RECEPTOR RECOGNIZING THE S37F MUTATION IN CTNNB1 AND ITS USE
WO2023196996A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
EP4573117A1 (en) 2022-08-18 2025-06-25 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
WO2024092265A2 (en) * 2022-10-28 2024-05-02 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ewsr1-wt1 fusion protein and uses thereof
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
AU2024310260A1 (en) 2023-06-29 2025-12-11 Dispatch Biotherapeutics, Inc. Synthetic cytokine receptors
WO2025240518A1 (en) 2024-05-14 2025-11-20 Dispatch Biotherapeutics, Inc. Modified lentiviral transfer plasmids
GB202406990D0 (en) * 2024-05-16 2024-07-03 Univ Oxford Innovation Ltd T cell receptors and uses thereof
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
ATE420112T1 (de) 1998-07-31 2009-01-15 Int Inst Cancer Immunology Inc Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU2003262094A1 (en) 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
US7575925B2 (en) 2002-12-10 2009-08-18 Sunnybrook Health Sciences Centre Cell preparations comprising cells of the T cell lineage and methods of making and using them
DK1731605T3 (da) 2004-03-31 2010-05-25 Int Inst Cancer Immunology Inc Cancerantigenpeptider der er afledt af WT1
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
CA3071740C (en) 2010-09-20 2020-09-08 Biontech Ag Antigen-specific t cell receptors and t cell epitopes
CN104395462B (zh) * 2012-05-03 2017-09-26 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
WO2014018863A1 (en) 2012-07-27 2014-01-30 The Board Of Trustees Of The University Of Illinois Engineering t-cell receptors
CN105377886B (zh) * 2013-01-29 2020-07-28 马克思-德布鲁克-分子医学中心（Mdc）柏林-布赫 识别mage-a1的高亲和力结合分子

Also Published As

Publication number Publication date
JP6712261B2 (ja) 2020-06-24
EP3177314B1 (en) 2020-10-07
CA2956545A1 (en) 2016-02-11
CN107074970A (zh) 2017-08-18
JP2018183175A (ja) 2018-11-22
US10538572B2 (en) 2020-01-21
US20160083449A1 (en) 2016-03-24
EP3177314A1 (en) 2017-06-14
CN107074970B (zh) 2021-07-30
WO2016022400A1 (en) 2016-02-11
JP2017523784A (ja) 2017-08-24

Similar Documents

Publication Publication Date Title
ES2841274T3 (es) Inmunoterapia con células T específica para WT-1
US11026969B2 (en) High affinity T cell receptors and uses thereof
JP6612963B2 (ja) 腫瘍抗原を直接認識するために組換えｔ細胞レセプターを使用するための組成物及び方法
ES2897731T3 (es) Composiciones y métodos para reforzar la eficacia de la inmunoterapia celular adoptiva
ES2870174T3 (es) Proteínas de fusión PD-1-CD28 y su uso en medicina
ES2904301T3 (es) Receptores de células T dirigidos contra Bob1 y usos de los mismos
ES2871400T3 (es) Células inmunitarias deficientes en SUV39H1
KR20220042161A (ko) Suv39h1에 결함이 있는 면역 세포
US20210340201A1 (en) Immunotherapy targeting kras or her2 antigens
WO2019055862A1 (en) HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF
CN110857319A (zh) 一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用
US20220267403A1 (en) Binding proteins specific for 5t4 and uses thereof
KR20230148837A (ko) Ror1 표적화 키메라 항원 수용체
US20230303974A1 (en) Immune Cells Defective for SOCS1
US20220009992A1 (en) T cell receptors specific for mesothelin and their use in immunotherapy
EP4456910A1 (en) Immune cells with inactivated suv39h1 and modified tcr
EP4353252A1 (en) Antigen-specific t cells by gene editing of cd3 epsilon
CN117412985A (zh) 靶向ror1的嵌合抗原受体
CN119894923A (zh) 包含tmigd2共刺激结构域的嵌合抗原受体及其相关使用方法
Nicholson Enhancing the efficacy of TCR gene therapy